Results 111 to 120 of about 885,175 (334)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data [PDF]

, 2022
Leanne Perez, Wolfram E. Samlowski, Ruby Lopez-Flores   +2 more
openalex   +1 more source

Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma

Journal of Cancer Research and Therapeutics, 2018
Clinical management of metastatic melanoma suffered historically from a lack of effective targeted and immunotherapies due to short-lived clinical responses.
Veerendra Koppolu, VeneelaKrishna Rekha Vasigala   +1 more
semanticscholar   +1 more source

Advances in Bioprinting to Model Immune‐Mediated Skin Diseases

Advanced Healthcare Materials, EarlyView.
This review explores how 3D bioprinting drives innovation in developing in vitro skin models that mimic immune‐mediated diseases. It highlights current technologies, key applications in studying skin pathologies, and emerging challenges. The review points toward future opportunities for improving disease modeling and advancing therapeutic and cosmetic ...
Andrea Ulloa‐Fernández, Marica Markovic, Julia Fernández‐Pérez, Georg Stary, Aleksandr Ovsianikov   +4 more
wiley   +1 more source

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Journal of Translational Medicine, 2017
BackgroundNivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients.MethodsIn this single-center retrospective analysis, we investigated the CD73 enzyme ...
S. Morello, M. Capone, C. Sorrentino, D. Giannarelli, G. Madonna, D. Mallardo, A. Grimaldi, A. Pinto, P. Ascierto   +8 more
semanticscholar   +1 more source

Evaluation of the Dual Impact of Nanotechnologies on Health and Environment Through Alternative Bridging Models

Advanced Healthcare Materials, EarlyView.
This review explores how alternative invertebrate and small‐vertebrate models advance the evaluation of nanomaterials across medicine and environmental science. By bridging cellular and organismal levels, these models enable integrated assessment of toxicity, biodistribution, and therapeutic performance.
Marie Celine Lefevre, Margherita Bernardeschi, Matteo Battaglini, Gianni Ciofani   +3 more
wiley   +1 more source

T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma

Pharmaceutics
Uveal melanoma represents a rare and aggressive subtype of melanoma with limited treatment options and poor prognosis, especially in the metastatic setting.
Robin Reschke, Alexander H. Enk, Jessica C. Hassel   +2 more
doaj   +1 more source

Metastatic cutaneus melanoma of the gallbladder: Case report [PDF]

, 2019
Veljanova Prgova, Bogoevska Nancheva, Beaka Bozinovska, Aleksandar Gjoreski, Jasminka Nancheva   +4 more
openalex   +1 more source

Immune-Mediated Adverse Effects in the Immunotherapy Treatment of Patients With Metastatic Melanoma Versus Adjuvant Regimen: A Study in a Daily Practice Setting

, 2023
Luisa Martos‐Cabrera, T. Gallego, Aurora Fernández‐Galván, Pedro Rodríguez‐Jiménez   +3 more
openalex   +1 more source

Bioorthogonal Photoactivation of 2‐Nitrobenzyl Caged Doxorubicin Anticancer Prodrugs on Gold Nanostars

Advanced Materials, EarlyView.
Bioorthogonal chemistry was applied to intracellularly photoactivate Doxorubicin (Dox) using gold nanostars (AuNSt) and near‐infrared (NIR) light. Two prodrugs were used: one photoactivatable, masked with 2‐nitrobenzyl carbamate (proDox1) and another photolabile, masked with 2‐nitrobenzyl diol (proDox2), which was attached to the AuNSt surface.
Juan José Esteve‐Moreno, Andrea Escudero, Oscar Ferreira Silvestre, José Manuel Terrés, Mónica Gorbe, Eva Garrido, Carlos Renero‐Lecuna, Judith Langer, María Alfonso, Javier Ibañez, Félix Sancenón, Roberto Cao‐Milán, Luis M. Liz‐Marzán, Alba García‐Fernández, Andy Hernández‐Montoto, Ramón Martínez‐Máñez   +15 more
wiley   +1 more source

Hypoxia-related Y RNA fragments as a novel potential biomarker for distinguishing metastatic oral melanoma from non-metastatic oral melanoma in dogs

Veterinary Quarterly
Hypoxia may promote tumor progression, and hypoxically altered noncoding RNA (ncRNA) expression may play a role in metastasis. Canine oral melanoma (COM) frequently metastasizes, and ncRNA expression under hypoxia may be clinically significant.
MD Nazmul Hasan, MD Mahfuzur Rahman, Al Asmaul Husna, Daiki Kato, Takayuki Nakagawa, Mohammad Arif, Naoki Miura   +6 more
doaj   +1 more source